← LIGAND PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||||
| Current assets: | |||||||||||
| Cash and Cash Equivalents, at Carrying Value | $18.8m | $20.6m | $117.2m | $71.5m | $47.6m | $19.5m | $45.0m | $23.0m | $72.3m | $174.9m | |
| Short-term Investments | $122.3m | $181.0m | $601.2m | $940.0m | $363.6m | $321.6m | $166.9m | $147.4m | $183.9m | $558.6m | |
| Inventory, Net | $1.9m | $4.4m | $7.1m | $7.3m | $26.5m | $27.3m | $13.3m | $24.0m | $14.1m | $9.1m | |
| Assets, Current | $163.1m | $237.0m | $870.5m | $1.1b | $500.6m | $464.8m | $263.6m | $237.4m | $331.6m | $832.3m | |
| Property, Plant and Equipment, Net | $1.8m | $4.2m | $5.4m | $7.2m | $14.4m | $20.5m | $12.5m | $15.6m | $15.1m | $3.6m | |
| Goodwill | $72.2m | $86.0m | $86.6m | $95.2m | $189.7m | $181.2m | $105.7m | $103.4m | $105.2m | $101.5m | |
| Intangible Assets, Net (Excluding Goodwill) | $204.7m | $228.6m | $219.8m | $210.4m | $595.3m | $551.0m | $342.5m | $299.6m | $266.6m | $225.4m | |
| Operating Lease, Right-of-Use Asset | — | — | — | $10.4m | $6.9m | $16.5m | $10.9m | $6.1m | $6.9m | $5.2m | |
| Other Assets, Noncurrent | $1.7m | $4.9m | $471k | $2.4m | $4.3m | $2.7m | $4.7m | $5.9m | $6.9m | $12.6m | |
| Additional Financial Items | |||||||||||
| Accounts Receivable, after Allowance for Credit Loss, Current | — | — | — | $30.4m | $56.8m | $85.5m | $30.4m | $32.9m | $38.4m | $59.6m | |
| Accrued Liabilities, Current | $6.4m | $7.4m | $19.2m | $9.8m | $18.5m | $17.6m | $15.7m | $12.5m | $27.9m | $31.5m | |
| Assets | $601.6m | $671.0m | $1.3b | $1.5b | $1.4b | $1.3b | $762.7m | $787.2m | $941.8m | $1.6b | |
| LIABILITIES AND EQUITY | |||||||||||
| Current liabilities: | |||||||||||
| Operating Lease, Liability, Current | — | — | — | $1.2m | $1.9m | $2.1m | $670k | $403k | $1.3m | $1.1m | |
| Accounts Payable, Current | $2.7m | $2.3m | $4.2m | $2.4m | $3.8m | $8.4m | $5.3m | $2.4m | $5.2m | $3.2m | |
| Operating Lease, Liability, Noncurrent | — | — | — | $10.0m | $5.6m | $15.5m | $10.3m | $5.8m | $5.8m | $4.2m | |
| Deferred Revenue, Noncurrent | — | $3.5m | — | — | — | — | $44k | $1.4m | $2.2m | $0 | |
| Liabilities, Current | $227.1m | $238.9m | $82.2m | $17.0m | $100.1m | $41.7m | $98.8m | $16.8m | $37.1m | $37.4m | |
| Deferred Income Tax Liabilities, Net | — | — | — | $32.9m | $64.6m | $59.1m | $30.6m | $31.6m | $32.5m | $36.0m | |
| Other Liabilities, Noncurrent | $687k | $723k | $951k | $22.5m | $30.9m | $31.0m | $22.0m | $27.8m | $30.2m | $16.6m | |
| Deferred Tax Liabilities, Net | — | — | — | $7.3m | $40.3m | $24.6m | $22.1m | $31.4m | $32.5m | $27.7m | |
| Liabilities | $230.7m | $252.4m | $699.9m | $727.7m | $652.8m | $476.4m | $165.2m | $86.3m | $111.3m | $543.4m | |
| Stockholders’ equity: | |||||||||||
| Preferred Stock, Value, Issued | — | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Common Stock, Value, Issued | $21k | $21k | $21k | $17k | $16k | $17k | $17k | $18k | $20k | $20k | |
| Additional Paid in Capital | $769.7m | $798.2m | $791.1m | $367.3m | $318.4m | $373.0m | $147.6m | $198.7m | $337.4m | $400.6m | |
| Retained Earnings (Accumulated Deficit) | ($431.1m) | ($400.9m) | ($229.2m) | $400.1m | $392.0m | $449.1m | $450.9m | $503.0m | $499.0m | $608.1m | |
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $2.7m | $2.5m | ($1.0m) | ($216k) | ($801k) | ($917k) | ($984k) | ($817k) | ($5.9m) | $8.5m | |
| Stockholders' Equity Attributable to Parent | $341.3m | $399.8m | $560.9m | $767.2m | $709.5m | $821.2m | $597.5m | $700.9m | $830.4m | $1.0b | |
| Liabilities and Equity | $601.6m | $671.0m | $1.3b | $1.5b | $1.4b | $1.3b | $762.7m | $787.2m | $941.8m | $1.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.